We investigated body size and survival by race/ethnicity in 11,351 breast cancer patients diagnosed from 1993 to 2007 with follow-up through 2009 by using data from questionnaires and the California Cancer Registry. We calculated hazard ratios and 95% confidence intervals from multivariable Cox proportional hazard model-estimated associations of body size (body mass index (BMI) (weight (kg)/height (m)
and LACE obtained only waist circumference measurements. For AABCS, SFBCS, and LACE, the mean time for postdiagnosis measurement was 1.7 (SD, 0.7) years; for CTS, the mean times were 3.8 (SD, 2.3) years prediagnosis (80% of the cohort) and 0.9 (SD, 0.6) years postdiagnosis (20% of the cohort).
Covariates. Variables based on self-report (categories shown in Table 1 ) included age at breast cancer diagnosis, race/ethnicity, education, birthplace, menopausal status, age at first birth, smoking history, alcohol intake, and comorbidities (diabetes, hypertension, and/or myocardial infarction). Information on marital status and a composite measurement of neighborhood socioeconomic status based on the distribution of census block groups within California was obtained from the CCR by using 2000 US Census data (23) .
Body size measures
Prediagnosis BMI was calculated for measurements at least 6 months before breast cancer diagnosis and categorized into 4-and 6-level BMI variables by using the World Health Organization international classifications (9, 24) . (25) . The 6-and 10-level variables were used to explore nonlinear BMI associations.
Waist-hip ratio (WHR) was calculated as waist circumference (in cm) divided by hip circumference (in cm) as a measurement of fat distribution that reflects adipose tissue and muscle mass. Waist-height ratio was calculated as waist circumference (in cm) divided by height (in cm) as a measurement of abdominal fat alone (26) . Waist circumference also estimates abdominal fat and is strongly correlated with BMI (27) . WHR, waist-height ratio, and waist circumference were categorized into quartiles.
Clinicopathologic and treatment factors
Variables from the CCR (categories in Table 2 ) included cancer stage, estrogen receptor and progesterone receptor status, nodal positivity, tumor grade, tumor size, prior cancer history, surgery type, and chemotherapy, hormonal therapy, and radiation therapy. Cancer stage was based on the staging system of the American Joint Committee on Cancer (Chicago, Illinois).
Study outcomes
Confirmation of vital status from the CCR was determined as of December 31, 2009 . Cases were not presumed to be alive if there was no documentation of death. Breast cancer-specific deaths were ascertained from information 96 Kwan et al. on the underlying cause of death on the death certificate based on International Classification of Diseases, Ninth Revision, codes 174-175 or International Classification of Diseases, Tenth Revision, code C50. Study endpoints included breast cancer-specific and all-cause mortality.
Analytical sample size BMI analyses were based on 11,351 women, excluding those without information on prediagnosis weight or adult height (n = 674) or other covariates (n = 185). Waist circumference analyses included 7, 191 women (from the AABCS, SFBCS, CTS, and LACE), excluding those with missing information (n = 1,610). WHR and waist-height ratio analyses included 5,720 and 7,180 women, respectively, excluding 3,081 and 1,621 women, respectively, with missing data. All missing covariate data were coded into "unknown" categories.
Statistical analysis
Before pooling data from the 3 case-control and 3 cohort studies, we conducted separate analyses by study design, and no systematic differences were found across studies. This was tested formally in our statistical models as an interaction term of race/ethnicity and study, and all likelihood ratio tests for this effect on mortality outcomes were P > 0.15 (11 df ) (15) .
Delayed entry Cox proportional hazards regression models with attained age as the time scale (28) and study as a stratification variable were used to estimate hazard ratios and 95% confidence intervals in overall and race/ethnicity-specific models. Although models were also run by using time from diagnosis as the time scale, attained age provided a slightly better model fit and was thus retained (15) . The entry date into the risk set was the latter of the date of questionnaire completion or the date of breast cancer diagnosis. The exit date was the date of death (breast cancer-specific or all-cause mortality, depending on analysis) or the end of follow-up (the earlier of the last follow-up date in the CCR or December 31, 2009 ).
Covariates were selected on the basis of backward stepwise regression and a priori determination from literature review. The order of removal was determined by the Cox partial likelihood test for that variable, and removal continued until all remaining variables had a likelihood ratio with P < 0.20. Final models were adjusted for all variables in Tables 1 and  2 , including treatment modalities of chemotherapy, radiation therapy, and hormonal therapy (no, yes, or unknown). For WHR, waist-height ratio, and waist circumference analyses, prediagnosis BMI and an indicator for prediagnosis or postdiagnosis WHR, waist-height ratio, or waist circumference measurement were also included.
Linear and nonlinear trends of BMI associated with each mortality outcome were obtained by modeling BMI as a continuous variable and using the partial likelihood test for linearity. To test whether the associations between each adiposity measure and mortality were modified by race/ethnicity, we constructed a likelihood ratio test for heterogeneity of trends comparing 2 multivariate Cox proportional hazard models (29) . Effect modification was evaluated in the associations between BMI, WHR, and mortality outcomes by menopausal status and hormone receptor status, and statistical significance was determined by the Wald test.
For analyses of breast cancer-specific mortality, we considered competing risks from non-breast cancer deaths to test extreme model violations under the independence assumption. For subjects who were censored because of non-breast cancer deaths, they were 1) assumed to have died of breast cancer instead, and 2) assumed to have survived as long as the longest survival time observed in the cohort. All tests of statistical significance were 2-sided, and P < 0.05 was considered statistically significant.
RESULTS
For BMI analyses, there were 1,445 breast cancer-specific deaths (2,744 deaths overall) after a mean follow-up of 11.0 (SD, 3.8) years. The mean time of weight and height measurements was 2.2 (SD, 0.5) years before diagnosis. For WHR analyses, there were 654 breast cancer-related deaths (1,284 deaths overall). The mean times of prediagnosis and postdiagnosis waist/hip measurement were 3.8 (SD, 2.3) years (n = 2,187) and 1.4 (SD, 0.7) years (n = 3,533), respectively.
Mean age at breast cancer diagnosis was 60.2 years, and two-thirds (66.4%) of cases were postmenopausal at diagnosis (Table 1) . About half (53.3%) were non-Latina white, and the mean prediagnosis BMI was 26.3. Compared with normal-weight women, obese women were more likely to be African American or Latina, older at breast cancer diagnosis, current or past smokers, nondrinkers, less educated, and US born and were more likely to reside in a low socioeconomic status neighborhood and to have a comorbidity. In contrast, underweight women were more likely to be younger at diagnosis, nonsmokers, college educated, and foreign born and not to have a comorbidity and to live in a higher socioeconomic status neighborhood at diagnosis.
The distribution of all clinicopathological and treatment characteristics varied significantly across BMI categories, except for chemotherapy (P = 0.16) ( Table 2) . Compared with normal-weight women, obese women were more likely to be diagnosed with advanced stage, poorly differentiated, and larger tumors and less likely to have had breast cancer surgery or to receive hormonal therapy. In contrast, underweight women were more likely to be diagnosed with lower stage, welldifferentiated, and smaller tumors, and not to receive hormonal therapy.
Although data are not shown, Asian Americans (44.7%) and Latinas (44.6%) were more likely to receive chemotherapy, followed by African Americans (40.4%) and nonLatina whites (38.8%). However, non-Latina whites were more likely to have radiation and hormonal therapy (56.4% and 44.2%, respectively) compared with the other groups. Asian Americans were least likely to have radiation (41.4%) and hormonal therapy (30.8%), followed by African Americans (radiation, 44.8%; hormonal therapy, 31.1%) and Latinas (radiation, 51.2%; hormonal therapy, 36.7%).
In fully-adjusted multivariate models, being underweight (HR = 1.41, 95% CI: 0.99, 2.02) or morbidly obese (HR = 1.42, 95% CI: 1.07, 1.88) was associated with an increased risk of breast cancer-specific mortality compared with being normal weight (Table 3) . Stronger results were found for allcause mortality (for underweight, HR = 1.47, 95% CI: 1.14, 1.91; for morbidly obese, HR = 1.41, 95% CI: 1.14, 1.75; P for trend = 0.04; P for departure from linearity = 0.004).
When assessing the impact of competing risks for breast cancer-specific mortality, we found that the hazard ratios were similar to the main hazard ratios above when making the following 2 assumptions about deaths not due to breast cancer: 1) subjects died of breast cancer, or 2) subjects survived for the longest time observed in the cohort (data not shown). Abbreviations: BMI, body mass index; SES, socioeconomic status. a BMI (weight (kg)/height (m) 2 ) was calculated from self-reported or measured prediagnosis weight at least 6 months before breast cancer diagnosis and self-reported or measured height at the time of the baseline/first postdiagnosis interview and categorized by using the following World Health Organization international classifications: underweight (<18.5), normal weight (18.5-24.9; reference), overweight (25.0-29.9), and obese (≥30.0).
b Values are mean (standard deviation). c A subset of women with BMI measurements had waist-related measurements. There were 403 women with waist-hip ratio measurements but no BMI measurements, 412 with waist-height ratio measurements but no BMI measurements, and 423 with waist circumference measurements but no BMI measurements (all not shown in table).
Women in the highest WHR quartile compared with those in the lowest quartile had an increased risk of breast cancer-specific mortality in the fully-adjusted model (HR = 1.27, 95% CI: 0.98, 1.65; P for trend = 0.04) ( Table 3) . For allcause mortality, the association with high WHR was stronger (HR = 1.30, 95% CI: 1.07, 1.57; P for trend = 0.001). Waistheight ratio and waist circumference were not associated with mortality outcomes. Again, when assessing the impact of competing risks, we found that the hazard ratios under both scenarios were similar to the main hazard ratios above (data not shown).
Similar to the overall cohort, non-Latina whites (for underweight, HR = 1.91, 95% CI: 1.14, 3.20; for morbidly obese, HR = 1.43, 95% CI: 0.84, 2.43) and Latinas (for underweight, HR = 1.40, 95% CI: 0.33, 5.92; for morbidly obese, HR = 2.26, 95% CI: 1.23, 4.15) had U-shaped associations of BMI with breast cancer-specific mortality, yet P for trends and departures from linearity were not statistically significant (Table 4) . When categorizing BMI into deciles, we found that the U-shaped associations among non-Latina whites and Latinas were less consistent with results based on the 6-level BMI categories for BMI of 30.0 or more. Overall, there were no BMI associations with breast cancer mortality in African Americans and Asian Americans. For all-cause mortality, statistically significant, increased risks in both the underweight and morbidly obese groups of non-Latina whites (for underweight, HR = 1.72, 95% CI: 1.22, 2.44; for morbidly obese, HR = 1.61, 95% CI: 1.12, 2.31; P for trend = 0.08; P for departure from linearity = 0.009) and Latinas (for underweight, HR=1.82, 95% CI: 0.72, 4.63; for morbidly obese, HR = 1.93, 95% CI: 1.21, 3.10; P for trend = 0.02; P for departure from linearity = 0.27) were found (Table 5) . However, no such associations were observed among Asian Americans and African Americans. Furthermore, after additional adjustment for WHR in a subset of women, all BMImortality associations remained consistent (data not shown).
Similar to the total cohort, high WHR was associated with increased risk of breast cancer-specific mortality in Asian Americans (HR = 2.21, 95% CI: 1.21, 4.03) with a significant linear trend (P = 0.01) ( Table 6 ). No WHR associations were apparent among African Americans, Latinas, and nonLatina whites. For all-cause mortality, although similar associations were observed for Asian Americans (HR = 1.64, Table 7) . The effects by prediagnosis versus postdiagnosis measurements in Asian Americans and African Americans could not be determined because of limited numbers (data not shown). Consistent with the overall cohort results, waist-height ratio and waist circumference were not associated with mortality in any racial/ ethnic group. No significant interactions of BMI, WHR, and breast cancer-specific mortality with hormone receptor status were observed ( Table 8 ). The BMI associations were also similar among premenopausal and postmenopausal women (data not shown). When these stratified analyses of hormone receptor and menopausal status were conducted within each racial/ ethnic group, no significant interactions were found (data not shown).
DISCUSSION
In this large, multiethnic study of 11,351 breast cancer patients, we found that those with very high or very low prediagnosis BMI or high WHR had the highest risk of death.
Compared with normal-weight women, both underweight and morbidly obese women had 1.4-fold greater risk of breast cancer-specific mortality, and women in the highest quartile of abdominal obesity had 1.3-fold greater risk of breast cancer-specific mortality. Our results suggest that the associations of obesity with mortality vary by measurement and degree of obesity, as well as by race/ethnicity. The U-shaped associations of BMI with breast cancer-specific mortality were suggestive among non-Latina whites and Latinas and were not observed in African Americans and Asian Americans. In contrast, high WHR was associated with elevated breast cancer-specific mortality after BMI adjustment among Asian Americans, but not African Americans, Latinas, or nonLatina whites. The results were stronger for all-cause mortality. Investigating these adiposity associations within the CBCSC allowed us to examine effects across 4 racial/ethnic groups, as well as by hormone receptor and menopausal status.
Reviews of BMI and breast cancer prognosis (4, 30, 31) report that roughly two-thirds of the studies conducted in the last decade have reported higher BMI at diagnosis as a significant risk factor for disease recurrence and mortality. Two meta-analyses have confirmed that obesity (BMI ≥30) preceding breast cancer diagnosis is related to breast 2 ) was calculated from self-reported or measured prediagnosis weight at least 6 months before breast cancer diagnosis and self-reported or measured height at the time of the baseline/first postdiagnosis interview and categorized by using the following World Health Organization international classifications: underweight (<18. cancer-specific mortality (HR range = 1.26-1.43) and all-cause mortality (HR range = 1.19-1.33) (2, 32) , and that the associations may be U-or J-shaped (33) . However, finer categories of obesity were not examined in these analyses. In a 2011 pooled analysis of 14,948 breast cancer survivors (34) , both underweight women (HR = 1.33, 95% CI: 0.92, 1.92) and morbidly obese women (HR = 1.40, 95% CI: 1.00, 1.96) had the greatest risks of breast cancer-specific mortality compared with normalweight women, and the associations with all-cause mortality were even stronger.
We know of only 3 studies to date that have examined BMI and mortality after breast cancer diagnosis by race/ethnicity (35-37), 2 of which are included in our analyses (35, 36) . No significant racial/ethnic differences of BMI and mortality were found in the MEC, which included an equal number of women from sites in Hawaii and California. However, (36) . BMI reflects the relationship of weight to height and does not completely capture the between-individual variation in total adiposity (38) . Few studies have examined the association of body fat distribution as measured by WHR with breast cancer survival in racial/ethnic minority populations. Three studies found an association of greater WHR with worse survival in primarily white premenopausal (39, 40) or postmenopausal (41) patients, whereas another study in Shanghai, China, found no association of WHR or waist circumference with survival (42) .
Ours is one of the first studies to report differences in the association between BMI, WHR, and mortality in the major US racial/ethnic groups. These findings most likely reflect the underlying heterogeneity of body composition for each racial/ ethnic group. When considering differences in body composition for survival studies, BMI might not be the most accurate adiposity measure in Asian Americans and perhaps in African Americans. Indeed, our observation of higher breast cancerspecific and/or all-cause mortality associated with high WHR in only these 2 racial/ethnic groups supports this notion and underscores the importance of using the most appropriate measurement to assess weight and adiposity by race/ethnicity. Several biological mechanisms have been proposed to underlie the effects of obesity on breast cancer outcomes (43, 44) , including higher circulating estrogens in obese (compared with nonobese) postmenopausal women (45, 46) , increases in insulin and insulinlike growth factors involved in the regulation of normal and malignant growth of epithelial breast cells (47, 48) , and adipose tissue as an important endocrine organ that secretes obesity-related regulatory proteins (adipokines) (49) (50) (51) . It is unclear why our analysis suggests a possible threshold effect by obesity level. We hypothesize that larger amounts of adipose tissue in the morbidly obese Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio. a Cox models with attained age as time scale and study as a stratification variable. Minimally adjusted models included age at breast cancer diagnosis, log of age at breast cancer diagnosis, and American Joint Committee on Cancer stage. Fully adjusted models also included race/ ethnicity, education, neighborhood socioeconomic status, place of birth, marital status, menopausal status, age at first birth, smoking history, alcohol intake, hormone receptor status, nodal positivity, tumor grade, tumor size, prior cancer history, surgery type, chemotherapy, radiation therapy, hormonal therapy, and comorbidity. Obesity and Mortality After Breast Cancer 103 . b P for homogeneity of BMI trend across racial/ethnic groups <0.001. c Cox models with attained age as the time scale and study as a stratification variable. Adjusted for age at breast cancer diagnosis, log of age at breast cancer diagnosis, American Joint Committee on Cancer stage, education, neighborhood socioeconomic status, place of birth, marital status, menopausal status, age at first birth, smoking history, alcohol intake, hormone receptor status, nodal positivity, tumor grade, tumor size, prior cancer history, surgery type, chemotherapy, radiation therapy, hormonal therapy, and comorbidity.
d Follow-up to death or end of follow-up (the earlier of the last follow-up date in the California Cancer Registry or December 31, 2009), whichever occurred first. e Prediagnosis BMI is in the following WHO BMI categories: underweight (<18.5), normal weight (18.5-24.9), overweight (25.0-29.9), obese (30.0-34.9), severely obese (35.0-39.9), and morbidly obese (≥40).
f For Asian Americans, the categories of obese, severely obese, and morbidly obese were combined into 1 category representing BMI of 30 or more. f For Asian Americans, the categories of obese, severely obese, and morbidly obese were combined into 1 category representing BMI of 30 or more. Abbreviations: CI, confidence interval; HR, hazard ratio. a Cox models with attained age as the time scale and study as a stratification variable. Adjusted for age at breast cancer diagnosis, log of age at breast cancer diagnosis, American Joint Committee on Cancer stage, education, neighborhood socioeconomic status, place of birth, marital status, menopausal status, age at first birth, smoking history, alcohol intake, hormone receptor status, nodal positivity, tumor grade, tumor size, prior cancer history, surgery type, chemotherapy, radiation therapy, hormonal therapy, and comorbidity, prediagnosis body mass index (weight (kg)/height (m) 2 ), and indicator of prediagnosis versus postdiagnosis waist-hip ratio, waist-height ratio, or waist circumference measurement. b Follow-up to death or end of follow-up (the earlier of the last follow-up date in the California Cancer Registry or December 31, 2009), whichever occurred first. Abbreviations: CI, confidence interval; HR, hazard ratio. a Cox models with attained age as the time scale and study as a stratification variable. Adjusted for age at breast cancer diagnosis, log of age at breast cancer diagnosis, American Joint Committee on Cancer stage, education, neighborhood socioeconomic status, place of birth, marital status, menopausal status, age at first birth, smoking history, alcohol intake, hormone receptor status, nodal positivity, tumor grade, tumor size, prior cancer history, surgery type, chemotherapy, radiation therapy, hormonal therapy, and comorbidity, prediagnosis body mass index (weight (kg)/height (m) compared with the moderately obese might create a more heightened, constant imbalance in obesity-related regulatory proteins and inflammatory cytokines. Furthermore, from the treatment perspective, obese women may be underdosed for chemotherapy because of toxicity-related concerns, resulting in reduced therapeutic response and worse outcomes (52) (53) (54) . Although we did observe treatment differences by race/ ethnicity and BMI in our cohort, adjustment for treatment modalities in our survival models did not substantially change the hazard ratios and 95% confidence intervals. A recent Surveillance Epidemiology and End Results-Medicare study also found that treatment differences explained few of the survival differences between non-Latina white and African American breast cancer patients aged 65 years and older, yet, similar to a limitation of our study, details of chemotherapy administration and hormonal therapy were not incorporated (55, 56) . Thus, further investigation of treatment differences is warranted.
Few studies have considered the biological mechanisms underlying associations of being underweight and having worse breast cancer outcomes. Underweight could be an indicator of preexisting comorbid conditions that have already placed these women at greater risk of poor outcomes (4). Although we adjusted for 3 common comorbid conditions (diabetes, hypertension, and myocardial infarction) and our mortality estimates did not differ by comorbidity, residual confounding by other unmeasured comorbidities is possible.
In a sensitivity analysis, we excluded deaths that occurred during the first 2 years after study enrollment, and elevated mortality risks remained in the underweight group for breast cancer-specific and all-cause mortality (HR = 1.4).
Strengths of this study include being the largest to date of racially and ethnically diverse breast cancer survivors, resulting in adequate power to examine potential associations of adiposity with mortality while adjusting for most known prognostic and treatment-related factors. Limitations were self-reported prediagnosis weight (yet substantial agreement between self-reported and measured weight has been shown (57)) and a lack of information on recurrent disease and associated treatments.
In conclusion, this large, multiethnic study confirms the overall association of obesity with mortality after breast cancer diagnosis, but the degree of obesity and body fat distribution at breast cancer diagnosis appear to have differential effects on mortality across racial/ethnic groups. BMI as a function of weight and height might better reflect a relationship to survival among non-Latina whites and Latinas, whereas WHR, a measure of central adiposity, may be a better index of obesity in relationship to survival among Asian Americans and perhaps African Americans. Future studies of racial/ethnic minorities and survival in breast cancer patients should incorporate multiple measurements of obesity to tease apart racial/ ethnic differences in body composition and mortality. 
